Trade Alibaba Health Information Technology Limited - 0241
Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical e-commerce, intelligent medicine, and product tracking platform businesses in the People's Republic of China. The company engages in the B2C pharmacy business that provides outsourced and value-added services, and other related services to the Tmall entities, and centralized procurement and distribution businesses. It also operates Drug PIATS, a product identification, authentication, and tracking system for the drug industry; and a medical services network, as well as offers online health consultation services. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. It has strategic collaboration agreement with Merck KGaA to develop patient-centric digital services. The company is based in Causeway Bay, Hong Kong. Alibaba Health Information Technology Limited is a subsidiary of Perfect Advance Holding Limited.Latest shares articles

BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026

TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026

Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026

Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026